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Abstract
Background: Hepatic expression of several gene products involved in glucose metabolism, including
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and insulin-like growth
factor binding protein-1 (IGFBP-1), is rapidly and completely inhibited by insulin. This inhibition is mediated
through the regulation of a DNA element present in each of these gene promoters, that we call the
Thymine-rich Insulin Response Element (TIRE). The insulin signalling pathway that results in the inhibition
of these gene promoters requires the activation of phosphatidylinositol 3-kinase (PI 3-kinase). However,
the molecules that connect PI 3-kinase to these gene promoters are not yet fully defined. Glycogen
Synthase Kinase 3 (GSK-3) is inhibited following activation of PI 3-kinase. We have shown previously that
inhibitors of GSK-3 reduce the activity of two TIRE-containing gene promoters (PEPCK and G6Pase),
whose products are required for gluconeogenesis.
Results: In this report we demonstrate that in H4IIE-C3 cells, four distinct classes of GSK-3 inhibitor
mimic the effect of insulin on a third TIRE-containing gene, IGFBP-1. We identify the TIRE as the minimum
requirement for inhibition by these agents, and demonstrate that the target of GSK-3 is unlikely to be the
postulated TIRE-binding protein FOXO-1. Importantly, overexpression of GSK-3 in cells reduces the
insulin regulation of TIRE activity as well as endogenous IGFBP-1 expression.
Conclusions: These results implicate GSK-3 as an intermediate in the pathway from the insulin receptor
to the TIRE. Indeed, this is the first demonstration of an absolute requirement for GSK-3 inhibition in
insulin regulation of gene transcription. These data support the potential use of GSK-3 inhibitors in the
treatment of insulin resistant states such as Type 2 diabetes mellitus, but suggest that it will be important
to identify all TIRE-containing genes to assess potential side effects of these agents.
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Background
Insulin-like growth factors (IGF-I and II) have a broad
range of biological activities that include the stimulation
of mitogenesis and differentiation, and insulin-like effects
on glucose uptake and lipogenesis [1]. These activities are
modulated by a family of six binding proteins, termed the
IGF-binding proteins (IGFBPs 1–6) that bind IGF-I and
IGF-II with high affinity (for review see [2]). IGFBP-1
binds and inhibits the activity of IGF-I and IGF-II in
plasma, by regulating their bioavailability [3]. Adminis-
tration of excess IGFBP-1, or overexpression of IGFBP-1 in
transgenic mice, leads to glucose intolerance and hyperin-
sulinaemia [4,5]. Meanwhile, IGFBP-1 expression can be
dynamically regulated by nutritional status, increasing
during fasting, malnutrition and diabetes but decreasing
upon re-feeding or insulin treatment [6-8]. Hepatic
IGFBP-1 gene transcription is rapidly and completely
inhibited by insulin [9,10], however, the signalling path-
way(s) that mediates this effect is less well defined. Insulin
induces multiple intracellular signalling pathways in liver.
Stimulation of the small G-protein Ras leads to activation
of a protein kinase cascade consisting of Raf-1, MAP
kinase kinase-1, p42/p44 MAP kinases and p90Rsk, while
the activation of phosphoinositide (PI) 3-kinase pro-
motes the generation of 3-phosphoinositides that induce
the activity of protein kinases such as 3-phosphoinositide
dependent kinase (PDK1) and protein kinase B (PKB)
[11,12]. PKB subsequently phosphorylates glycogen syn-
thase kinase -3 (GSK-3) at an N-terminal serine residue
(Ser-21 on GSK-3α and Ser-9 on GSK-3β) rendering it
inactive [13,14]. This PKB-mediated inhibition of GSK-3
contributes to insulin activation of glycogen and protein
synthesis [14,15].
Studies using inhibitors of PI 3-kinase have demonstrated
a requirement for this enzyme in insulin regulation of
IGFBP-1 [16]. Indeed, overexpression of an active mutant
of PKB mimics the effects of insulin on the IGFBP-1 pro-
moter [16]. This effect, at least in part, is mediated
through the inhibition of a Thymine-rich Insulin
Response Element (TIRE) that lies between residues -120
and -96 relative to the transcription start site of the human
gene promoter. Phosphoenolpyruvate carboxykinase
(PEPCK) and Glucose-6-Phosphatase (G6Pase), rate-con-
trolling enzymes of hepatic gluconeogenesis, possess a
related regulatory element within their gene promoters
[17]. Interestingly, members of the FOX(O) family of
transcription factors (FKHR/FKHR-L1/AFX) have been
linked to the regulation of the TIRE's found in these pro-
moters [18,19]. The expression of all of these genes, as
well as the regulation of FOX(O), is inhibited by insulin
through a PI 3-kinase-dependent mechanism [20-24],
suggesting that a common signalling pathway is utilised
by insulin to regulate these related TIREs. However, insu-
lin regulation of IGFBP-1 but not G6Pase or PEPCK gene
expression is sensitive to an inhibitor of the mammalian
Target of Rapamycin (mTOR) [10,25]. In addition, agents
that strongly induce the MAPK pathway (e.g. phorbol
esters) [26], as well as the protein phosphatase inhibitor
okadaic acid [27], reduce the sensitivity of the IGFBP-1,
but not the G6Pase and PEPCK promoters to insulin.
Therefore, aspects of the signalling networks used by insu-
lin to repress each of these TIRE containing promoters
appear distinct. Recently, we observed that GSK-3 activity
was required for both PEPCK and G6Pase promoter activ-
ity [28]. Selective inhibitors of GSK-3 reduce PEPCK and
G6Pase gene transcription without requiring the activa-
tion of PKB. Indeed, the inhibition of GSK-3 may explain
some of the effects of PKB overexpression on PEPCK and
G6Pase gene expression. However, it was not clear why
inhibition of GSK-3 should repress these promoters,
whether inhibition of GSK-3 was actually required for
insulin regulation of the genes, and whether the effect of
GSK-3 inhibition was mediated through the TIRE.
In the present study, we have examined the role of GSK-3
in the regulation of a third TIRE-containing gene pro-
moter, namely IGFBP-1. We demonstrate that four differ-
ent classes of inhibitors of GSK-3 can mimic the action of
insulin and reduce IGFBP-1 gene expression. Further-
more, we find that inhibition of GSK-3 reduces the activity
of a heterologous promoter containing the IGFBP-1 TIRE,
and propose that this mechanism underlies the repression
of all three promoters by inhibitors of GSK-3. Finally, we
demonstrate for the first time a requirement for inhibition
of GSK-3 in the insulin regulation of the TIRE, and hence
IGFBP-1 expression.
Results
Lithium ions reduce IGFBP-1 gene expression in H4IIE cells
Treatment of H4IIE cells with insulin completely inhibits
both basal and glucocorticoid-induced IGFBP-1 gene
expression. Lithium chloride, an inhibitor of GSK-3 in
vivo, reduces both basal and glucocorticoid-induced
IGFBP-1 gene expression (Fig 1). The effect of 20 mM lith-
ium is not as complete as observed with insulin, resulting
in only a 60–70% reduction of IGFBP-1 gene expression.
However, treatment of H4IIE cells with the same concen-
tration of potassium chloride has no effect on IGFBP-1
expression. The cyclophilin mRNA levels remain
unchanged throughout these experiments. This highlights
a role of a target of lithium ions in the specific regulation
of IGFBP-1 gene expression.
More selective inhibitors of GSK-3 also reduce IGFBP-1 
gene expression
SB 214763 and SB 415286 are cell-permeable maleimide
compounds that selectively inhibit GSK-3 [29]. Treatment
of H4IIE cells with either compound reduces IGFBP-1
gene expression (Fig 2). Expression is more sensitive to SBBMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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214763 than SB 415286 (consistent with its lower IC-50
towards GSK-3 in vitro [29]). Importantly, cyclophilin
mRNA levels remain unchanged in the presence of these
compounds. Furthermore, under these conditions the reg-
ulatory phosphorylations of PKB and FOXO-1 are unaf-
fected by SB214763, SB415286 or lithium [28]. In
addition, SB214763 or SB415286 do not affect the phos-
phorylation of Ser-9 (GSK-3β) or Ser-21 (GSK-3α). Simi-
larly, MAPK and S6K activity are not significantly affected
by these compounds, as judged by the phosphorylation
status of these insulin-regulated signalling molecules (Fig
3). Hence, the effects seen with these compounds on
IGFBP-1 are likely to be due to the inhibition of GSK-3
rather than as a consequence of down/up-regulation of
PKB, FOXO-1, MAPK or the mTOR pathway, which are
known to effect IGFBP-1 gene expression.
Paullones are potent inhibitors of GSK-3 that reduce 
IGFBP-1 gene expression
Paullones are a family of benzazepinones that are potent
(IC50; 20–200 nM), ATP-competitive inhibitors of cyclin-
dependent kinases (CDKs) and the closely related neuro-
nal CDK5/p25 [30-32]. Subsequently, they have been
shown to be very potent inhibitors of GSK-3β [33]. Two
members of this family, kenpaullone and alsterpaullone,
reduce IGFBP-1 gene expression in a dose dependent
manner (Fig 4). Alsterpaullone is much more potent than
kenpaullone, reducing IGFBP-1 mRNA levels by 90% at 5
µM compared to a 50% reduction seen with 10 µM ken-
paullone (Fig 4). Once more, this is consistent with the
lower IC50 of alsterpaullone toward GSK-3 in vitro [33].
Alsterpaullone (like the maleimides) does not affect the
phosphorylation of PKB, FOXO-1, MAPK, S6K or S6 (Fig
5). Similarly, phosphorylation at residues Ser-9 (GSK-3β)
and Ser-21 (GSK-3α) of GSK-3 is unaffected by alster-
paullone treatment (Fig 5). Phosphorylation of Thr-308
(PKB) correlates with the activation of PKB while phos-
phorylation of Ser-9 (GSK-3β), Ser-21 (GSK-3α) and Thr-
32 (FKHRL1) is indicative of inhibition of these PKB
substrates.
CHIR99021, the most specific GSK-3 inhibitor reported to 
date, also represses IGFBP-1 gene expression
Although alsterpaullone, kenpaullone, SB214763, and
SB415286 are potent inhibitors of GSK-3, they also
exhibit activity against CDKs. However, the aminopyrimi-
dine CHIR99021 shows 350-fold selectivity toward GSK-
3 compared to CDKs (Jenny Bain and Sir Philip Cohen,
University of Dundee, personal communication), and
exhibits a Ki of < 10 nM in vitro [34]. It is the most selec-
tive inhibitor of this enzyme reported to date [34,35].
Treatment of H4IIE cells with CHIR99201 dramatically
reduced basal and glucocorticoid-induced IGFBP-1 gene
transcription, at concentrations between 1 and 10 µM (Fig
6)
Lithium ions reduce IGFBP-1 gene expression Figure 1
Lithium ions reduce IGFBP-1 gene expression. H4IIE cells were 
starved overnight prior to a 3 h incubation with insulin,10 
nM; lithium chloride or potassium chloride at the concentra-
tions indicated with or without dexamethasone, 500 nM; (A-
B). Total cellular RNA was isolated and an RNase protection 
assay was performed as described in material and methods. 
Results are presented as percentage gene expression (A) or 
fold induction (B) relative to control and are means ± stand-
ard error of two experiments performed in duplicate (upper 
panels). Representative experiments (lower panels) are also 
shown. ***, p < 0.001, **, p < 0.01 and NS, not significantBMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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CHIR99021 reciprocally regulates β-catenin activity and 
IGFBP-1 gene transcription
H4IIE cells were transiently transfected with a luciferase-
reporter construct containing TCF/LEF binding sites,
whose activity is regulated by the GSK-3 substrate, β-cat-
enin. Inhibition of GSK-3 results in the accumulation of
β-catenin in the cytoplasm where it can form complexes
with TCF/LEF. The complex translocates to the nucleus
and activates transcription of target genes. Treatment of
transfected H4IIE cells with CHIR99021 results in a dose-
dependent increase in luciferase activity, regulated by the
β-catenin/TCF complex (Fig 7A). The β-catenin mediated
transcription is induced two-fold by 2 µM CHIR99021,
reaching six to seven-fold at 10 µM. Therefore the concen-
tration required to induce β-catenin activity is equivalent
to that required for reduction of endogenous IGFBP-1
mRNA (Fig 6).
Meanwhile, insulin treatment of H4IIE cells previously
transfected with a luciferase reporter construct under the
control of a thymidine kinase promoter containing the
IGFBP-1 TIRE (BP-1WT), reduces luciferase expression by
60% (Fig 7B). This effect is abolished by a two base pair
mutation of the TIRE (BP-1DM5) (Fig 7B and [36]). Inter-
estingly, 2 µM CHIR99021 reduces BP-1 WT activity by
around 50% (Fig 7B), while 10 µM inhibits luciferase
expression by 70%, with no effect on BP-1 DM5 activity.
This demonstrates that CHIR99021 reduces TIRE activity,
at a concentration that also induces β-catenin-mediated
gene transcription (2–10 µM). This strongly argues that
the effects of CHIR99021 on TIRE activity are mediated
through inhibition of GSK-3.
Enhanced expression of GSK-3 reduces insulin regulation 
of the IGFBP-1 TIRE
In order to assess the requirement for inhibition of GSK-3
in insulin regulation of the IGFBP-1 TIRE we over
expressed wild-type GSK-3 (GSK-3β-WT), insulin-insensi-
tive GSK-3 (GSK-3β-S9A) or control protein (β-galactosi-
dase) in H4IIE cells using adenoviral vectors. Infected cells
SB216763 and SB415286 reduce IGFBP-1 gene expression Figure 2
SB216763 and SB415286 reduce IGFBP-1 gene expression. H4IIE cells were starved overnight prior to a 3 h incubation with insu-
lin, 10 nM ; dexamethasone, 500 nM; plus or minus SB216763 (A) or SB415286 (B) at the concentrations shown. Total cellular 
RNA was isolated and an RNase protection assay was performed, as described in material and methods. Results are presented 
as fold induction relative to control (serum free) and are means ± standard error of two experiments performed in duplicate 
(upper panels). Representative experiments are also shown (lower panels). ***, p < 0.001 and * p < 0.05BMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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were subsequently transfected with BP-1-WT and treated
with or without insulin (Fig 8A). The inhibitory effect of
insulin on the BP-1 TIRE was significantly reduced when
GSK-3 was over expressed (Fig 8A), demonstrating that
inhibition of GSK-3 is required for full repression of this
element by insulin. Both wild-type (p < 0.001) and S9A-
GSK-3 (p < 0.001) over expression (around 3 to 5-fold
increase in expression) reduced insulin regulation of this
element. Meanwhile, adenoviral expression of GSK-3β-
S9A also reduced the ability of insulin to repress IGFBP-1
mRNA in the H4IIE cells (Fig 8B).
CHIR99021 does not regulate FOXO-1 transactivation 
potential
BP-1 TIRE activity can be regulated by co-expression of
FOXO-1 [22,36]. Therefore, we examined the effect of
CHIR99021 on the ability of FOXO-1 to regulate TIRE
activity. When FOXO-1 is co-expressed with BP-1 WT in
H4IIE cells, the expression of luciferase is induced around
3-fold (Fig 9). Insulin inhibits this FOXO-1-induced luci-
ferase activity, while sensitivity to 2 µM CHIR99021 is
completely lost in the presence of co-expressed FOXO-1
(Fig 9). The concentration of FOXO-1 used is less than
maximal for induction of the BP-1 WT. This data suggests
that FOXO-1 overexpression desensitises the TIRE to
CHIR99021 and therefore that GSK-3 does not signifi-
cantly regulate FOXO-1 activity.
Discussion
GSK-3 activity is required for IGFBP-1 promoter activity 
through direct regulation of the TIRE
This study demonstrates that six agents, of four different
chemical classes, which share an ability to inhibit GSK-3
mimic the effect of insulin on IGFBP-1 gene expression.
Inhibition of GSK-3 does not affect the phosphorylation of MAPK or regulation of the mTOR pathway Figure 3
Inhibition of GSK-3 does not affect the phosphorylation of MAPK or regulation of the mTOR pathway. H4IIE cells were serum starved 
overnight prior to incubation with insulin, 10 nM; lithium chloride, 20 mM; SB216763, 30 µM; or SB415286, 100 µM for 15 min 
(A) or 3 h (B). Cells were lysed, and the lysates subjected to SDS PAGE as described in materials and methods, transferred to 
nitrocellulose and immunoblotted with antibodies as labelled (Phospho; phosphospecific antibody). Similar results were 
obtained from two experiments carried out in duplicateBMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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This is reminiscent of the effect of lithium ions, SB216763
and SB415286 on two other insulin repressed gene pro-
moters, PEPCK and G6Pase [28]. Indeed, a heterologous
promoter containing the IGFBP-1 TIRE (a related
sequence is common to all three of these insulin-regulated
gene promoters), is also inhibited by CHIR99021 (Fig
7B). Similar promoter sequences are important for the
insulin regulation of the tyrosine aminotransferase [37],
aspartate aminotransferase [38], IRS-2 [39], and HMG
CoA Synthase [40] gene promoters. Our data would pre-
dict that all of these genes, and any other promoters
containing a TIRE, are likely to be repressed by treatment
of cells with inhibitors of GSK-3. This provides an appar-
ent paradox since we and others have found that insulin
does not regulate every TIRE-containing gene promoter by
an identical mechanism. For example, insulin regulation
of the IGFBP-1 (but not the PEPCK or G6Pase) gene pro-
moter requires mTOR activity [10,25,26]. Meanwhile,
FOXO-1 is a TIRE-binding protein that has been proposed
to regulate these three genes. However, cells that stably
overexpress FOXO-1 show increased G6Pase but not
PEPCK expression [41], and genetic manipulation of
FOXO-1 has differential effects on these three gene pro-
moters [19]. These data demonstrate that distinct signal-
ling mechanisms control the regulation of these three
TIRE-containing genes. Therefore, each TIRE structure
may require GSK-3 activity for function but distinct sig-
nalling networks link each gene promoter with the insulin
receptor. The common requirement for GSK-3 activity
suggests that a GSK-3 substrate is key for the initiation of
gene transcription for each TIRE-containing promoter.
Paullones reduce IGFBP-1 gene expression Figure 4
Paullones reduce IGFBP-1 gene expression. H4IIE cells were serum starved overnight prior to a 3 h incubation with insulin,10 nM; 
dexamethasone, 500 nM; plus or minus kenpaullone (A) or alsterpaullone (B) at the concentrations shown. Total cellular RNA 
was isolated and an RNase protection assay was performed, as described in material and methods. Results are presented as 
fold induction relative to control (serum free) and are means ± standard error of two experiments performed in duplicate 
(upper panels). Representative experiments are also shown (lower panels). ***, p < 0.001 and ** p < 0.01BMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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Alsterpaullone does not affect the regulatory phosphorylation sites of PKB, FOXO-1, MAPK, and components of the mTOR  pathway Figure 5
Alsterpaullone does not affect the regulatory phosphorylation sites of PKB, FOXO-1, MAPK, and components of the mTOR pathway. 
H4IIE cells were serum starved overnight prior to incubation with 10 nM insulin, or alsterpaullone at the concentrations shown 
for 30 min (A) or 3 h (B). Cells were lysed, and the lysates subjected to SDS PAGE, transferred to nitrocellulose and immuno-
blotted with antibodies as labelled (Phospho; phosphospecific antibody). Similar results were obtained from two experiments 
carried out in duplicateBMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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Inhibition of GSK-3 is required for full inhibition of the 
IGFBP-1 TIRE by insulin
Insulin induces PKB activity, promoting phosphorylation
of Ser-21 of GSK-3α and Ser-9 of GSK-3β, thereby
reducing total GSK-3 activity by between 20 and 80%,
dependent on cell type. Therefore, expression of a mutant
GSK-3β with Ser-9 replaced by alanine renders cellular
GSK-3 activity insensitive to insulin [14]. Indeed, expres-
sion of this mutant significantly reduces the ability of
insulin to repress BP-1 WT (Fig 8A), or the endogenous
gene promoter (Fig 8B), demonstrating that insulin
CHIR99021 reduces IGFBP-1 gene expression Figure 6
CHIR99021 reduces IGFBP-1 gene expression. H4IIE cells were 
serum starved overnight prior to a 3 h incubation with insu-
lin,10 nM; dexamethasone, 500 nM; 8CPT-cAMP, 0.1 mM; 
plus or minus CHIR99021 at the concentrations shown. 
Total cellular RNA was isolated and an RNase protection 
assay was performed to measure IGFBP-1 and cyclophilin 
mRNA, as described in material and methods. Representative 
experiments are shown (A), while results are presented (B) 
as % expression (after correction for cyclophilin expression), 
relative to control (serum free) and are means ± standard 
error of two experiments performed in duplicate.
CHIR99021 regulates both β-catenin activity and TIRE con- taining promoter activity Figure 7
CHIR99021 regulates both β-catenin activity and TIRE containing 
promoter activity. H4IIE cells were transfected with TOPFlash 
(A) or alternatively with BP-1 WT or BP-1 DM5 (B) reporter 
constructs. Cells were incubated for 24 h with 10 nM insulin 
or CHIR99021 at the concentrations shown, prior to lysis 
and luciferase assays as described in materials and methods. 
Results are presented as fold induction relative to basal luci-
ferase activity (no inhibitor) (A) or % luciferase activity rela-
tive to basal (serum free) luciferase expression (B) and are 
the means ± standard error of at least two experiments per-
formed in triplicate. The basal activity of BP-1 WT and BP-1 
DM5 is not significantly different.BMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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requires to inhibit GSK-3 for full repression of this gene
promoter element. Similarly, four to five fold over expres-
sion of wild-type GSK-3β antagonises insulin repression
of the BP-1 WT (Fig 8A). Although insulin will promote
phosphorylation and inhibition (50–60% in H4IIE cells)
of this recombinant GSK-3 in cells, the overall activity
remains higher than un-stimulated control cells. This sug-
gests that insulin must reduce GSK-3 activity below a
threshold in order to fully repress BP-1 WT. This is the first
demonstration of an absolute requirement for GSK-3
inhibition in insulin regulation of gene transcription.
What is the molecular link between GSK-3 and the TIRE?
The GSK-3 inhibitors regulate IGFBP-1 gene expression in
the absence of regulation of PKB, MAP kinase, FOXO-1 or
mTOR ([28] and Figs 3 and 4), known regulators of the
IGFBP-1 promoter. This suggests a more direct regulation
of this element, possibly of a TIRE-interacting protein
itself. There are numerous transcription factors that have
been proposed to be substrates for GSK-3 in vitro and in
some cases in vivo (for review see [42]). These include β-
catenin, c-jun, CREB, glucocorticoid receptor (GR) and c-
Overexpression of GSK-3β reduces insulin regulation of the  IGFBP-1 TIRE Figure 8
Overexpression of GSK-3β reduces insulin regulation of the IGFBP-
1 TIRE. H4IIE cells were infected with adenovirus expressing 
either β-Galactosidase (control), GSK-3β (GSK-3wt), or 
insulin-insensitive GSK-3β (GSK-3S9A). A) Cells were incu-
bated for 16 hours before transfection with 10 µg of BP-1 
WT as described under the Methods section. After 24 hours 
at 37°C +/- insulin (10 nM) cells were lysed and either luci-
ferase assays performed (upper panel) or GSK-3 levels deter-
mined by Western Blot (lower panel). Results in the upper 
panel are presented as % insulin repression of luciferase 
expression and are the means +/- S.E.M. of at least five 
experiments performed in duplicate or triplicate. Basal luci-
ferase expression is 3-fold higher in WT and S9A-GSK-3 
infected cells compared with control. The lower panels pro-
vide a representative analysis of expression of GSK-3 (in trip-
licate) in each treatment. There was a significant reduction in 
the effect of insulin on BP-1 WT when either GSK-3 WT 
(***p < 0.001, control vs WT) or GSK-3 S9A (***p < 0.001, 
control vs S9A) was overexpressed. There is no significant 
difference between the WT and S9A data sets (p = 0.160). B) 
After infection cells were incubated for 24 hr prior to a 3 hr 
incubation with hormones as indicated. Cells were lysed and 
IGFBP-1 and cyclophilin mRNA levels assessed by RNase 
Protection Assay. A representative experiment is shown 
(lower panel), while relative mRNA levels ± SEM are pre-
sented for two experiments performed in duplicate in the 
upper panel.
CHIR99021 does not affect FOXO-1 transactivation  potential Figure 9
CHIR99021 does not affect FOXO-1 transactivation potential. 
H4IIE cells were transfected with BP-1WT along with 
pEBG2T or pEBG2T-FOXO-1. Cells were incubated with 10 
nM insulin or 2 µM CHIR99021 for 24 h prior to lysis and 
luciferase assays as described in materials and methods. 
Results are presented as % luciferase activity relative to basal 
(serum free) luciferase expression and are the means ± S.E. 
of two experiments performed in triplicate. NS; not 
significant.BMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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myc. The phosphorylation of β-catenin [43,44], c-jun
[45,46], GR [47] and c-myc [48] by GSK-3 promotes their
destruction or reduces their activity, while the phosphor-
ylation of CREB (at Ser-129) is thought to increase CREB
activity [49], although this has been subsequently ques-
tioned [50]. Since inhibition of GSK-3 reduces TIRE activ-
ity, one presumes that GSK-3 mediated phosphorylation
of a TIRE-binding protein would result in its activation
(although possibly a permissive effect allowing activation
by an additional mechanism), nuclear localisation or sta-
bilisation. This would seem to rule out β-catenin, c-jun,
GR and c-myc in the GSK-3-mediated regulation of the
TIRE. Meanwhile CREB does not bind directly to a TIRE in
vitro. The only known GSK-3 substrates that have been
demonstrated to bind to or regulate the TIRE are members
of the CAAT-enhancer binding protein (C/EBP) family of
transcription factors. GSK-3 phosphorylates C/EBPα at
Thr-222/Thr-226 [51] while C/EBPβ can regulate TIRE
activity and is itself regulated by insulin [52]. The reported
regulation of C/EBPβ by insulin is PI 3-kinase and PKB-
dependent but is mediated through phosphorylation of
the co-regulator protein p300/CBP [52]. We are currently
examining whether the GSK-3 inhibitors regulate C/EBP
and p300 phosphorylation and/or activity. Meanwhile,
Granner and colleagues have found that insulin treatment
of H4IIE cells increases the cellular levels of LIP (an
inhibitory form of C/EBPβ that lacks the p300/CBP bind-
ing and activation domain) [53]. LIP subsequently
replaces LAP (the activating form of C/EBPβ) on the
endogenous PEPCK promoter. This prevents the
recruitment of RNA polymerase II and p300/CBP, eventu-
ally leading to the repression of PEPCK gene expression.
However, the LIP/LAP interacting elements within the
PEPCK promoter are distinct from the TIRE [53]. Finally,
our data suggests that the effect of GSK-3 inhibitors is
independent of regulation of FOXO-1 (Figs 4 and 9), the
best characterised TIRE-binding protein. Therefore, much
more work will be required to identify the GSK-3 substrate
that regulates this DNA element.
GSK-3 inhibitors as therapeutics
Agents that mimic the physiological processes that are reg-
ulated by insulin have the potential to be of therapeutic
value for the treatment of insulin resistant states such as
diabetes. Lithium chloride, SB216763, SB415286 and
CHIR99021 inhibit GSK-3 and therefore mimic many of
the actions of insulin. For instance, lithium chloride stim-
ulates glucose transport and glycogen synthesis in
adipocyte and muscle cell lines [54-56], while SB216763
and SB415286 stimulate glycogen synthesis in hepato-
cytes [29]. Meanwhile, CHIR99021 potentiates insulin
activation of glucose transport and utilisation in vitro and
in vivo [34], and related compounds reduce muscle insu-
lin resistance [57] in animal models of diabetes. We have
found that GSK-3 inhibitors also mimic the ability of
insulin to repress key metabolic genes such as PEPCK,
G6Pase and IGFBP-1 ([28] and Figs 1, 2 and 4). Studies in
animal models of diabetes suggest that these agents allevi-
ate hyperglycaemia through both activation of glycogen
synthesis and inhibition of hepatic glucose production
[58,59]. However, a vast number of biological processes
are known to be regulated by GSK-3, thereby questioning
their long term use as regulators of glucose homeostasis.
Importantly, GSK-3 associates with and regulates proteins
linked to the development of colonic cancer (APC, axin
and β-catenin). Meanwhile, ablation of one of the two
genes for GSK-3 (GSK-3β) in mice proved to be fatal due
to increased hepatic sensitivity to TNFα-induced
apoptosis [60]. Despite all of the potential problems that
may be associated with GSK-3 inhibitors, deleterious
effects of such compounds in animals remain to be for-
mally reported. Currently, GSK-3 inhibitors are being
investigated for the treatment of numerous psychiatric
disorders [61,62], neurodegeneration [63,64] and even
hair loss [65].
Conclusions
The work presented herein demonstrates for the first time
that inhibition of GSK-3 is required for complete insulin
regulation of IGFBP-1, while we have identified the DNA
element by which GSK3 targets this gene promoter. As
such, GSK-3 inhibition will mimic the insulin regulation
of IGF1 bio-availability, as well as reducing the expression
of hepatic gluconeogenic genes. It remains to be seen how
many other insulin-regulated (and/or TIRE-containing)
gene promoters are sensitive to these inhibitors.
Methods
Materials
Radioisotopes were obtained from Amersham, Bucks, UK
({γ32P}-ATP) and ICN, Thame, Oxfordshire, UK ({α32P}-
UTP). Insulin was purchased from Novo Nordisk,
(Crawley, West Sussex, UK), kenpaullone and alster-
paullone from Calbiochem (La Jolla, CA) and the RNase
Protection Assay Kit II from AMS Biotech/Ambion, (Aus-
tin, Texas). All other chemicals were of the highest grade
available.
Synthesis of CHIR 99021
CHIR99021 (6-{2-[4-(2,4-Dichloro-phenyl)-5-(4-
methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino]-ethyl-
amino}-nicotinonitrile) was synthesized in 7% overall
yield using a convergent approach from 2,4-dichloroben-
zoyl chloride and 6-chloro nicotinonitrile respectively
([66] and refs within).
Cell Culture
The rat hepatoma cell line H4IIE was maintained in Dul-
becco's Modified Eagle's medium (DMEM) containing
1000 mg/l glucose, 5% (v/v) foetal calf serum, asBMC Molecular Biology 2004, 5:15 http://www.biomedcentral.com/1471-2199/5/15
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described previously [67]. Cells were incubated with hor-
mones, at 37°C, for the times and at the concentrations
indicated in the figure legends.
RNA isolation and RNase protection assay
H4IIE cells were serum-starved overnight and treated with
hormone/inhibitor for the times and at the concentra-
tions indicated in the figure legends. Total cellular RNA
was isolated using TriReagent™ (Sigma) following the
manufacturer's instructions. An RNase Protection Assay
(RPA) was performed to determine the relative amounts
of IGFBP-1 and cyclophilin mRNA in each sample [26].
Band intensity was quantified on a phosphorimager
(Fuji), data calculated as a ratio of IGFBP-1 to cyclophilin
mRNA and presented as fold activation (for induced sam-
ples) where the intensity of control samples were set at
one, or as % gene expression (for non-induced samples)
where the level of gene expression in untreated cells is set
at 100%.
Preparation of cell extract for western blot
H4IIE cells were incubated in serum-free medium with
hormones and inhibitors for the times and at the concen-
trations indicated in the figure legends. Cells were then
scraped into ice-cold lysis buffer (25 mM Tris/HCl, pH
7.4, 50 mM NaF, 100 mM NaCl, 1 mM sodium vanadate,
5 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 10 mM
sodium pyrophosphate, 1 mM benzamidine, 0.1 mM
PMSF, 0.27 M sucrose, 2 µM microcystin and 0.1% (v/v)
2-mercaptoethanol). Cell debris was removed by centrifu-
gation at 13000 × g for 5 min and the protein concentra-
tion determined by the method of Bradford, using BSA as
an internal standard.
Antibodies for western blot analysis
Antibodies to phospho ribosomal protein S6 (Ser-235),
phospho-FKHR-L1 (Thr-32) and GSK-3β were purchased
from Upstate (Lake Placid, USA), while the phospho-spe-
cific Ser9/Ser21 GSK-3, Thr-308 PKB, Thr389-S6K1, and
Thr-183/Tyr185 p42/p44 MAPK antibodies were
purchased from Cell Signalling Technologies (Hertford-
shire, UK). H4IIE cell lysates were prepared following
incubation with hormones as described in figure legends
and analysed by Western blot analysis.
Plasmids
The plasmids BP-1 WT and BP-1 DM5 were a gift from Dr
Robert Hall and Professor Daryl K. Granner (Vanderbilt
University, TN, USA) [36]. The BP-1 WT plasmid repre-
sents a luciferase reporter construct under the control of a
thymidine kinase promoter containing the IGFBP-1 TIRE
wild-type sequence (5'-CAAAACAAACTTATTTTG). Two
base pair mutations of the wild-type TIRE sequence at res-
idues equivalent to position 5 of each A and B site (5'-
CAAAAGAAACTTCTTTTG) produces a mutant promoter
(BP-1 DM5) that is no longer responsive to insulin [36].
The FOXO-1 constructs have been described previously
(10).
Transient transfections
The TOPflash reporter plasmid kit were obtained from
Upstate Biotechnology (Lake Placid, USA). TOPflash has
Tcf binding sites driving luciferase expression.
Tranfections were performed using the calcium phosphate
procedure as described previously [10]. H4IIE cells were
transfected in 10 cm dishes with BP-1 WT (10 µg), BP-1
M5 (10 µg), TOPFlash (10 µg), plus or minus 2 µg of GST-
FOXO-1 as indicated. Cells were then incubated for 24 h
in serum free media with or without hormones or inhibi-
tors as described in figure legends. Cells were lysed in 300
µl lysis buffer (Promega, UK), the cell debris removed by
centrifugation at 13000 × g for 2 min and the supernatant
stored at -70°C. Luciferase assays were performed using
the firefly luciferase assay system (Promega, UK), as per
manufacturer's instructions, with luciferase activity being
corrected for the protein concentration in the cell lysate.
Adenoviral infection
H4IIE cells were infected with virus between a titre of 108
and 109 plaque forming units per ml, incubated at 37°C
for 16 hr. Cells were then transfected with 10 µg of BP-1
WT as described above and incubated for a further 24 hr
in the presence or absence of 10 nM insulin. Luciferase
was harvested and assayed or cell extracts were prepared
for western blot analysis, as described earlier.
Statistical analyses
As a measure of statistical significance of differences in
experimental groups, student t-tests were performed and
5% confidence limits applied.
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